Four Scientific Sessions Highlighted HIFU for Treatment of Prostate Cancer HIFU Featured in Plenary Lecture and Two Moderated Posters at Engineering and Urology Society Meeting Significant Interest in both HIFU and ESWL Technologies at EDAP Booth LYON, France, May 14, 2013 (GLOBE NEWSWIRE) -- EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic ultrasound, highlighted its positive reception at the American Urological Association (AUA) 2013 Annual Meeting, held in San Diego on May 4-8, 2013. At the meeting, four scientific abstracts were presented regarding the outcomes for HIFU treatment of prostate cancer, and two regarding clinical use of the Sonolith lithotripter and its exclusive ultrasound Visio Track ® localization system. Two of the HIFU posters, #1208 and #1496, entitled The importance of biopsies in ablation therapies for prostate cancer: Start of salvage treatment for persistent positive biopsies after HIFU and HIFU treatment outcomes for localized prostate cancer from the first European centers, respectively, received Best Poster awards from the AUA. On May 4, 2013, at the 28th Annual Meeting of the Engineering and Urology Society, held in conjunction with AUA, two posters highlighting HIFU were presented by Pr. Christian Chaussy of the University Regensburg, Germany. In addition, Pr. Chaussy gave an invited plenary session on long term results of HIFU for localized prostate cancer from his over 15 year experience with the procedure. Mr. Oczachowski, EDAP's Chief Executive Officer, said, "We are proud that two of our Ablatherm-HIFU posters received the best poster award during the AUA. This is clear academic recognition of HIFU as a valuable technology for treating prostate cancer and reflects positively on the high level of research supporting Ablatherm-HIFU. This is a key differentiation point for EDAP, and reinforces our established leadership in HIFU for the treatment of prostate cancer both from a technological and clinical standpoint."